BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17332357)

  • 1. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
    Koehler H; Kofler D; Hombach A; Abken H
    Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
    Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+ and CD8+ naïve human T-cells.
    Gunnlaugsdottir B; Maggadottir SM; Ludviksson BR
    Int Immunol; 2005 Jan; 17(1):35-44. PubMed ID: 15557315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation.
    Sepulveda H; Cerwenka A; Morgan T; Dutton RW
    J Immunol; 1999 Aug; 163(3):1133-42. PubMed ID: 10415007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor beta 1 costimulated growth and regulatory function of staphylococcal enterotoxin B-responsive CD8+ T cells.
    Rich S; Seelig M; Lee HM; Lin J
    J Immunol; 1995 Jul; 155(2):609-18. PubMed ID: 7608539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naïve CD4+ T cells.
    Sung JL; Lin JT; Gorham JD
    Int Immunopharmacol; 2003 Feb; 3(2):233-45. PubMed ID: 12586604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential activation of CD8+ T cells by transforming growth factor-beta 1.
    Lee HM; Rich S
    J Immunol; 1993 Jul; 151(2):668-77. PubMed ID: 8335902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated human CD4+ T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-beta: implications for dendritic cell immunization against cancer.
    Lin CM; Wang FH; Lee PK
    Clin Immunol; 2002 Jan; 102(1):96-105. PubMed ID: 11781072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
    Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
    J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
    Chmielewski M; Hombach AA; Abken H
    Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
    Habib-Agahi M; Jaberipour M; Searle PF
    Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
    Birkholz K; Hombach A; Krug C; Reuter S; Kershaw M; Kämpgen E; Schuler G; Abken H; Schaft N; Dörrie J
    Gene Ther; 2009 May; 16(5):596-604. PubMed ID: 19158846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
    Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
    J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
    Kosiewicz MM; Alard P; Liang S; Clark SL
    Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.